Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Eli Lilly and Company
Julio Rosenstock; Carol Wysham; Juan P Frías; Shizuka Kaneko; Clare J Lee; Laura Fernández Landó; Huzhang Mao; Xuewei Cui; Chrisanthi A Karanikas; Vivian T Thieu